MGC Pharma's Shares Climb Following Positive ArtemiC Results on COVID-19

At the beginning of this week, we discussed what positive results would look like for MGC Pharma's novel formula 'ArtemiC' in treating patients with COVID-19. Now, the results are in. Let's unpack them.

On Tuesday, we discussed what to look out for in MGC Pharmaceuticals (ASX:MXC) upcoming interim double-blind phase II randomized clinical trial on COVID-19 patients using their novel formula 'ArtemiC,' a natural supplement formula based on Artemisinin, Curcumin and other supporting ingredients.

We mentioned that the formula has several positive things going for it, which are as follows:

  • MGC Pharma's recent animal studies revealed that ArtemiC is non-toxic.
  • As anti-vaccine sentiments continue to grow, ArtemiC could be a potential treatment for COVID-19 that doesn't require vaccination.
  • The company has distribution agreements in place to get ArtemiC to market immediately, should MGC meet positive endpoints with the trials.

Though of course, all of these points are contingent on whether or not ArtemiC can actually help patients suffering from COVID-19. Now, the results are in, so let's see whether MGC has cause for celebration.

When we last discussed ArtemiC's potential to be a viable treatment for COVID-19, we mentioned that investors should keep their eyes peeled for results that indicate ArtemiC's ability to reduce the body's inflammatory response to COVID-19, also known as a 'cytokine storm,' as this is what often leads to hospitalizations from the virus.

Well, the company has achieved exactly that.

The Company's recent announcement revealed that "ArtemiC can reduce the risk of inflammation by diminishing the release of the interleukins (IL-1β and IL-6) from PBMCs in response to standard stimulation by exposure to Lipopolysaccharide (LPS). Interleukins trigger inflammation and modulate the immune response, and Lipopolysaccharide (LPS) is an agent that causes the production of cytokines that leads to cytokines storm."

WCAG 2.1 new guidelines simplified | by Sean Elliott | Medium

For those without a science degree, a lot of that can look like word-salad. However, the key takeaway is that ArtemiC is showing a real potential to reduce the factors which contribute to creating a cytokine storm.

As we mentioned earlier in the week, this could be massive for both MGC Pharma and the world at large, as cytokine storms often lead to to COVID-19 hospitalizations and fatalities, by causing Acute Respiratory Distress Syndrome. By reducing the likelihood of this inflammatory response, COVID-19 patients may experience more manageable symptoms, and the likelihood of hospitals becoming overwhelmed is reduced worldwide.

Speaking on the results, MGC's Co-founder and Managing Director, Roby Zomer commented: "We are very pleased to have achieved these results, which have been completed in line with FDA requirements for COVID-19 studies and provide important data points for our Phase IIb and III trial design and protocols."

Understandably, this could be massive for MGC Pharma, who is currently awaiting the first interim results from the COVID-19 infected patients from the Phase II randomised, double-blind clinical trial underway in Israel, which are expected to come out soon.

Could MGC Pharma's 'ArtemiC' fill the enormous demand for a COVID-19 treatment?

Disclaimer: Past performance is not an indicator of future performance.

Get the Latest Marijuana News &
Content in your Inbox!

All your support helps The Green Fund keep writing content for all you
marijuana enthusiasts and potential pot stock investors

Louis O'Neill
Louis O'Neill

Louis is a writer based in Sydney with a focus on social and political issues. Having interviewed local politicians and entrepreneurs, Louis now focuses on cannabis culture, legislation & reform.

Leave a Reply

Your email address will not be published. Required fields are marked *